grade
pharmaceutical primary standard
API family
lynestrenol
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
SMILES string
O[C@@]1([C@@]2([C@H]([C@H]3[C@@H]([C@H]4CCCC=C4CC3)CC2)CC1)C)C#C
InChI
1S/C20H28O/c1-3-20(21)13-11-18-17-9-8-14-6-4-5-7-15(14)16(17)10-12-19(18,20)2/h1,6,15-18,21H,4-5,7-13H2,2H3/t15-,16+,17+,18-,19-,20-/m0/s1
InChI key
YNVGQYHLRCDXFQ-XGXHKTLJSA-N
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Lynestrenol EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
Still not finding the right product?
Explore all of our products under 利奈孕酮
法规信息
新产品
此项目有
Yasir Hasan Siddique et al.
Indian journal of experimental biology, 43(3), 291-293 (2005-04-09)
Genotoxicity study of synthetic progestin lynestrenol, was carried out on mouse bone marrow cells using sister chromatid exchanges (SCEs) and chromosomal aberrations (CAs) as parameters. Lynestrenol was studied at three different doses (6.87, 13.75 and 27.50 mg/kg body wt.). SCE
Ozlem Ozdegirmenci et al.
Gynecologic and obstetric investigation, 72(1), 10-14 (2011-01-27)
To evaluate the treatment of endometrial hyperplasia (EH) with different progestins. Eighty-two women with simple EH without atypia were included. Patients were offered oral progestagens and were randomized to one of three options for 3 months: medroxyprogesterone acetate (MPA, 10
Eva-Katrin Bentz et al.
Fertility and sterility, 94(7), 2688-2696 (2010-06-12)
To evaluate gene expression signatures of breast tissue in female-to-male (FtM) transsexuals under cross-sex hormone therapy (HT). Prospective cohort study. Academic research institution. Five hormone-naïve FtM transsexuals before and after HT. Breast tissue biopsy before and after 2 years of
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| L0800000 | 04061833812327 |